RBC Capital analyst Brian Abrahams is a fan of Gilead Sciences (GILD) — in particular, its Biktarvy 3-in-1 drug cocktail for treating HIV-1.It is “Biktarvy’s strong profile and robust launch, along with favorable demographic and pricing dynamics,” that Abrahams says “will underpin good HIV franchise sustainability through at least 2025” for Gilead Sciences. Combined with the company’s better known continued hepatitis-C drug franchise, which is experiencing declining revenue but market share and pricing stability, and should therefore be able to generate “~$17B in cash flows over the next decade,” says the analyst, Gilead Sciences is likely to outperform the market.At …read more
Source:: Yahoo Finance
